- Home
- KOD vs ATYR Comparison
KOD vs ATYR Comparison
Compare KOD & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOD | ATYR |
|---|---|---|
| Founded | 2009 | 2005 |
| Country | United States | United States |
| Employees | 121 | 59 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 83.3M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | KOD | ATYR |
|---|---|---|
| Price | $23.22 | $0.84 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 8 |
| Target Price | ★ $28.29 | $4.20 |
| AVG Volume (30 Days) | 503.1K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.60 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9,628.95 |
| Revenue Next Year | N/A | $156.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.92 | $0.64 |
| 52 Week High | $31.18 | $7.29 |
Technical Indicators
Market Signals| Indicator | KOD | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 43.50 |
| Support Level | $21.19 | $0.82 |
| Resistance Level | $29.17 | $0.85 |
| Average True Range (ATR) | 1.70 | 0.07 |
| MACD | -0.35 | -0.02 |
| Stochastic Oscillator | 8.59 | 7.78 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).